Immune targeting of three independent suppressive pathways (TIGIT, PD-L1, TGFβ) provides significant antitumor efficacy in immune checkpoint resistant models

Immune checkpoint blockade (ICB) therapy, while groundbreaking, must be improved to promote enhanced durable responses and to prevent the development of treatment-refractory disease. Cancer therapies that engage, enable, and expand the antitumor immune response will likely require rationally designe...

Descripción completa

Detalles Bibliográficos
Autores principales: Franks, S. Elizabeth, Fabian, Kellsye P., Santiago-Sánchez, Ginette, Wolfson, Benjamin, Hodge, James W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542338/
https://www.ncbi.nlm.nih.gov/pubmed/36211806
http://dx.doi.org/10.1080/2162402X.2022.2124666

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542338/
https://www.ncbi.nlm.nih.gov/pubmed/36211806
http://dx.doi.org/10.1080/2162402X.2022.2124666

Ejemplares similares